An immunoassay kit and its preparation method and detection method
By developing a kit that can detect Syndecan-4 and KL-6 proteins simultaneously, combining these proteins as joint detection indicators of RA-ILD, the problem of insufficient sensitivity and specificity of existing RA-ILD diagnostic methods has been solved, and the problem of further development has been achieved. High diagnostic accuracy and condition assessment.
Patent Information
- Application Number
- CN202410450086.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-15
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-04-15
AI Technical Summary
The existing RA-ILD diagnostic methods have low sensitivity and specificity, making it difficult to effectively evaluate the incidence and disease activity of RA-ILD. The existing KL-6 detection methods are insufficient in Chinese patients and cannot meet the needs of sensitivity and specificity. Higher diagnostic needs.
A kit was developed that can simultaneously detect the content of Syndecan-4 and KL-6 proteins, using recombinant proteins and monoclonal antibodies to improve the sensitivity and specificity of the detection through western blot detection, combining Syndecan-4 and KL- 6 proteins are used as a joint detection indicator to improve the diagnostic accuracy of RA-ILD.
It improves the sensitivity and specificity of RA-ILD diagnosis, has a higher compliance rate than a single detection indicator, and can more accurately evaluate the disease activity and prognosis of RA-ILD, enhancing the reliability of the diagnosis.
Smart Images

Figure CN118294678B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular relates to a diagnostic kit for RA-ILD and its application. Background Art
[0002] Rheumatoid arthritis (RA) is a chronic autoimmune disease of unknown cause, with a global incidence of 0.5% to 1.0% and a Chinese incidence of 0.42%. It is one of the main causes of loss of labor and disability in the Chinese population. The lungs are rich in collagen fibers and blood vessels, making them an organ that RA patients are more likely to invade. Almost any part of the respiratory tract may be affected. Among them, combined interstitial lung disease (ILD) is the most common lung manifestation in RA patients and the main cause of death in RA patients. [Wang Congying, Han Rui, Li Jingfang, et al. Research progress in the pathogenesis, diagnosis and treatment of interstitial lung disease associated with rheumatoid arthritis [J]. Journal of Tianjin University of Traditional Chinese Medicine, 2022, 41(2):8]. Therefore, it is of great clinical significance to find some simpler, more repeatable examination methods to evaluate the incidence, disease activity and severity of RA-ILD.
[0003] Yang Jinliang and his team tested serum sialylated sugar chain antigen-6 (Krebs Von den Lungen-6, KL-6) levels and found that compared with patients with rheumatoid arthritis (RA) alone, patients with combined interstitial lung disease (RA-ILD) had significantly increased KL-6 levels. In addition, the study also showed that serum KL-6 levels were correlated with 28 joint disease activity scores, suggesting that the incidence of RA-ILD increases with the increase in joint disease activity. Therefore, KL-6 may serve as a diagnostic marker for RA-ILD.
[0004] In Japan, the positive rate of KL-6 serum levels in various diseases has established a clinical critical value of 500U / mL, which is used to distinguish ILD patients from healthy people and non-ILD lung disease patients. In the consensus of Japanese experts, the threshold of KL-6 is usually set at 500U / mL. When the KL-6 level exceeds 500U / mL, it can be used as a sensitive and specific indicator for the diagnosis of ILD. In China, some studies have shown that KL-6 can be used as a serological marker for ILD in Chinese patients. With 500U / mL as the diagnostic cut-off value, the sensitivity and specificity of KL-6 reached 77.75% and 94.51%. KL-6 helps predict the risk of death from ILD. The higher the KL-6 level, the worse the prognosis of ILD. It can be used to assess the activity of ILD and predict disease progression and clinical outcomes.
[0005] In order to further improve the sensitivity and specificity of RA-ILD diagnosis, it is necessary to develop a new detection kit for the detection and prognostic indicators of RA-ILD. Summary of the invention
[0006] In order to make up for the deficiencies of the prior art, the object of the present invention is to provide a kit for RA-ILD and a preparation method and application thereof.
[0007] Therefore, on one hand, the present invention discloses a kit for detecting RA-ILD, which can simultaneously detect the content of Syndecan-4 protein and KL-6 protein, and the kit comprises an effective amount of KL-6 recombinant protein, an effective amount of Syndecan-4 protein, an effective amount of monoclonal antibodies against Syndecan-4 protein and KL-6 protein, an effective amount of monoclonal antibodies against Syndecan-4 protein, an effective amount of monoclonal antibodies against KL-6 protein, and matching detection reagents.
[0008] Preferably, the amino acid sequence of the KL-6 recombinant protein of the present invention is shown as SEQ ID NO.1, wherein the codon-optimized nucleotide sequence of the KL-6 recombinant protein is shown as SEQ ID NO.2.
[0009] Preferably, the monoclonal antibody against Syndecan-4 protein and KL-6 protein of the present invention is monoclonal antibody-2, wherein the amino acid sequences of the heavy chain variable region and the light chain variable region of monoclonal antibody-2 are shown in SEQ ID NO.4 and SEQ ID NO.5.
[0010] Preferably, the monoclonal antibody-2 of the present invention binds to the Syndecan-4 protein at aa1 to aa20, and its amino acid sequence is IRETEVIDPQDLLEGRYFSG.
[0011] Preferably, the monoclonal antibody-2 of the present invention binds to the KL-6 protein at aa231 to aa250, and its amino acid sequence is ISDVSVSDVPFPFSAQSGAG.
[0012] Preferably, the monoclonal antibody-2 of the present invention is coupled to magnetic particles.
[0013] Preferably, the anti-KL-6 protein monoclonal antibody of the present invention is monoclonal antibody-6, wherein the amino acid sequences of the heavy chain variable region and the light chain variable region of monoclonal antibody-6 are shown in SEQ ID NO.6 and SEQ ID NO.7.
[0014] Preferably, the monoclonal antibody-6 of the present invention is labeled with FITC.
[0015] In another aspect, the present invention also discloses a use of the KL-6 recombinant protein in the preparation of a KL-6 diagnostic reagent.
[0016] In another aspect, the present invention also discloses the use of the monoclonal antibody-2 in the preparation of diagnostic reagents for Syndecan-4 protein and KL-6 protein.
[0017] The kit for RA-ILD detection prepared by the present invention has good sensitivity and specificity, and has a better compliance rate than the single detection of Syndecan-4 protein and KL-6 protein. At the same time, the monoclonal antibody-2 disclosed in the present invention has good sensitivity to both Syndecan-4 protein and KL-6 protein, and can be used for the detection of Syndecan-4 protein and KL-6 protein. The monoclonal antibody-6 disclosed in the present invention has good sensitivity and specificity to KL-6 protein, and can be used for the detection of KL-6 protein. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 The results of SDS-PAGE detection of KL-6 recombinant protein, where 1 is the marker and 2 is the purified KL-6 recombinant protein.
[0019] Figure 2 Amino acid sequence comparison analysis results of Syndecan-4 protein and KL-6 protein.
[0020] Figure 3 Western blot results of monoclonal antibody-2 against Syndecan-4 protein and KL-6 protein.
[0021] Figure 4 Western blot results of monoclonal antibody-6 against Syndecan-4 protein and KL-6 protein. DETAILED DESCRIPTION
[0022] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.
[0023] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents and materials used in the following examples are commercially available.
[0024] Example 1: Preparation of KL-6 recombinant protein
[0025] As mentioned in
[0004] to
[0005] of CN 116535488 A regarding the poor stability of KL-6, the researchers analyzed the amino acid sequence of P15941·MUC1_HUMAN and combined it with the results of CN 116535488 A Figure 1 Regarding the description of MUC1, the signal peptide, transmembrane region, intracellular region and other regions were removed, and the remaining amino acid sequence (as shown in SEQ ID NO.1) was retained, which contained 1 VNTR and SEA region, and a 6His tag was added to the C-terminus to facilitate nickel column purification.
[0026] The codon-optimized KL-6 recombinant protein nucleotide sequence (shown in SEQ ID NO.2) was selected as a template, and BamHI and XhoI restriction sites were inserted, and then the target gene and vector pFastBac1 were double-digested and connected. The ligation product was transformed into E. coli DH5α competent cells, positive bacteria were selected for amplification and culture, and the recombinant plasmid (pFastBac1-E1) was extracted. The positively identified recombinant plasmid was added to E. coli DH10Bac competent cells for transposition, and white spot bacteria were selected for identification and culture to obtain recombinant Bacmid. Under the action of transfection reagent Cellfectin ReagentⅡ, Sf9 insect cells were transfected to obtain the recombinant baculovirus seed virus P0 generation.
[0027] The P0 seed virus was inoculated with a cell suspension and inoculated into SF9 cells in good growth condition (confluence > 80%) at a ratio of MOI = 1. The cells were cultured at 28°C and 120 rpm for 96 hours with shaking. If the cells showed obvious pathological changes (the cells became larger and rounder), the cell culture fluid was collected and cultured for two consecutive generations to obtain the P2 generation seed virus.
[0028] The P2 seed virus was inoculated into High5 cells at 2% of the inoculation volume to a cell density of 2.0×10 6 / ml, shake and culture at 28℃, 120rpm for 120 hours, collect the cell culture fluid after the cells are completely broken, centrifuge at 6000r / min, 4℃ for 10 minutes, and take the supernatant for use. Purify the protein with a nickel column, elute with 250mM imidazole solution, collect the eluate; dialyze and replace the solution (1×PBS buffer), then pass through a 0.22μm filter membrane for sterilization, and store at -80℃ for use.
[0029] After the above steps, KL-6 recombinant protein was successfully prepared and purified ( Figure 1 The yield after purification was about 150 mg / L.
[0030] The stability of the KL-6 recombinant protein prepared by the present invention at 37°C was studied according to the method of paragraphs
[0087] to
[0092] of Experimental Example 1 of CN 116535488 A. The results are shown in Table 1. The stability of the KL-6 recombinant protein prepared by the present invention is better than that of the quality control product prepared by CN 116535488 A (it can be stored at 37°C for 42 days, while the control quality control product can be stored for 30 days).
[0031] Table 1 Stability comparison results (37℃ storage time / day)
[0032]
[0033] Example 2: Detection of Syndecan-4 protein expression in RA-ILD
[0034] It has been reported in the literature that Syndecan-4 protein is a good differential diagnostic marker (Li Juan, Tan Liming. The diagnostic value of Syndecan-4 in the differentiation of patients with rheumatoid arthritis [J]. Everyone's Health, 2023 (4): 108-110), and its sensitivity is 86.5% and specificity is 64.2%. To this end, the researchers tested the expression level of Syndecan-4 in RA-ILD (refer to the methods and kits in the literature). The results showed that in RA-ILD, Syndecan-4 protein was highly expressed, and its sensitivity and specificity were 80.7% and 52.5%, respectively.
[0035] According to the above results, the researchers envisioned using Syndecan-4 protein and KL-6 protein as a combined detection index for the diagnosis of RA-ILD, thereby improving the sensitivity and specificity of RA-ILD diagnosis. However, the sensitivity and specificity of existing detection kits for Syndecan-4 protein and KL-6 protein are relatively poor. For this reason, the present invention simultaneously develops a diagnostic kit for Syndecan-4 protein and KL-6 protein for the detection of Syndecan-4 protein and KL-6 protein.
[0036] Example 3: Syndecan-4 protein and KL-6 protein detection kit
[0037] 1. Preparation of monoclonal antibodies
[0038] The amino acid sequences of Syndecan-4 protein (amino acid sequence as shown in SEQ ID NO.3) and KL-6 protein were compared and analyzed ( Figure 2), the two proteins have a similar sequence, and two antigen epitope peptides were designed and synthesized, one for Syndecan-4 protein (amino acid sequence IRETEVIDPQDLLEGRYFSG, position aa1~aa20), and the other for KL-6 protein (amino acid sequence ISDVSVSDVPFPFSAQSGAG, position aa231~aa250). After the two peptides were artificially synthesized, they were mixed in equal mass ratios to prepare vaccines. Female BALB / c mice aged 6 to 8 weeks were immunized for a total of three immunizations, all of which were subcutaneously injected at multiple points. The antigen immunization dose per mouse was 100 μg each time, and the first immunization was emulsified with an equal amount of Freund's complete adjuvant, the second immunization was emulsified with an equal amount of Freund's incomplete adjuvant, and the third immunization was mixed with an equal amount of physiological saline and injected intraperitoneally. Blood was collected 7 days after the third immunization, and the antibody titer was measured by indirect method to determine whether antibodies against Syndecan-4 protein and KL-6 protein were produced at the same time. Compare the titers of mice, and finally select mice with higher antibody titers for cell fusion. Through testing, a mouse with a titer of 1:10000 was screened. The spleen of the screened mice was taken, and the spleen cells were fused with myeloma cells to screen hybridoma cells. After screening and testing, a good hybridoma cell was screened. This hybridoma cell was used to prepare mouse ascites and monoclonal antibodies.
[0039] Healthy female mice aged 6 to 7 weeks were intraperitoneally injected with 0.5 ml of liquid paraffin. After 7 to 10 days, each mouse was intraperitoneally injected with 1 × 10 6 Hybridoma cells were collected after observing the mouse status for 7 to 10 days when the mouse abdominal cavity was obviously swollen. The supernatant was the ascites, which was packaged, labeled and used for later use. The ascites was centrifuged for 15 minutes (4000rpm, room temperature), and the supernatant was taken and purified using a Protein G column. The purified antibody was measured by the BCA method, and stored at -80℃ for later use after packaging.
[0040] The monoclonal antibody prepared above (denoted as monoclonal antibody-2) was used for western blot detection of Syndecan-4 protein (MCE Company, catalog number: HY-P73623) and KL-6 recombinant protein (prepared in Example 1). Monoclonal antibody-2 had good specificity and sensitivity to both Syndecan-4 protein and KL-6 recombinant protein. Figure 3 At the same time, the sequence of the monoclonal antibody-2 was detected and analyzed, and the sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody-2 were shown in SEQ ID NO.4 and SEQ ID NO.5.
[0041] According to the above method, the KL-6 recombinant protein prepared in Example 1 was used as an immunogen to immunize mice and screen hybridoma cell lines, and a monoclonal antibody was prepared, which was recorded as monoclonal antibody-6. The monoclonal antibody was used to perform western blot detection on Syndecan-4 protein and KL-6 recombinant protein. The results were ( Figure 4 ) The monoclonal antibody-6 has no specific binding reaction with the Syndecan-4 protein, but has a specific reaction with the KL-6 recombinant protein. At the same time, the sequence of the monoclonal antibody-6 is detected and analyzed, and the sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody-6 are shown in SEQ ID NO.6 and SEQ ID NO.7.
[0042] 2. Preparation of Syndecan-4 protein and KL-6 protein detection kit
[0043] (1) Monoclonal antibody-2 coupled magnetic particles: Take 1 mg of carboxyl magnetic particles (purchased from thermo), wash three times with 0.1 M MES buffer, and resuspend with 0.5 ml MES (pH 6.0) buffer. Add 10 μg of monoclonal antibody-2, mix well, and incubate at room temperature with shaking for 20 min. Add 10 μl of EDC (10 mg / ml), mix well, and incubate at room temperature for 2 h. After centrifugation, discard the supernatant, add 500 μl of washing buffer (TBST buffer), and wash three times. Block with TBST buffer containing 1% BSA at room temperature for 2 h. After washing three times with TBST, resuspend with 0.5 ml of TBST buffer containing 1% BSA and store at 4°C for use.
[0044] (2) FITC-labeled monoclonal antibody-6: The antibody to be labeled (concentration ≧1 mg / ml) was dialyzed three times against the labeling reaction solution (90 mM NaHCO3, 10 mM Na2CO3, 126 mM NaCl, pH 9.0) at 4°C. FITC (purchased from Sigma) was dissolved in anhydrous DMSO to 1 mg / ml. The FITC used for cross-linking should be freshly prepared each time and stored at 4°C in the dark. FITC was slowly added to the antibody solution according to the ratio of antibody / protein: FITC = 1 mg: 150 μg, and gently shaken while adding to mix it with the antibody. The reaction was carried out at 4°C in the dark for 8 hours. 5 M NH4Cl was added to a final concentration of 50 mM, and the reaction was terminated at 4°C for 2 hours. The labeled product was dialyzed in PBS for more than 3 times until the dialyzate was clear. After dialysis, 0.1% NaN3, 1% BSA, and 30% glycerol were added. The product was stored at 4°C in the dark for a short period of time and at -20°C in the dark for a long period of time.
[0045] (3) Kit composition: as shown in Table 2.
[0046] Table 2 Kit composition
[0047]
[0048] Note: Syndecan-4 protein (MCE, catalog number HY-P73623); PE Anti-Syndecan 4 antibody (ab279590).
[0049] (4) Kit detection: The specific detection steps are as follows:
[0050] 1) Preparation of standard (prepare 7 1.5mL EP tubes numbered 2.3.4.5.6.7.8 respectively), as shown in Table 3:
[0051] ① Take 200 μL of the standard into tube 1 as the highest concentration of the standard, 5000 U / mL.
[0052] ② Add 150 μL of standard / sample diluent to each of the other 7 EP tubes (No. 2 to 8) to prepare gradient dilutions of the standard.
[0053] ③ Transfer 50μL of the standard in tube 1 to tube 2 and mix thoroughly, then transfer 50μL from tube 2 to tube 3 and mix thoroughly. Dilute continuously to tube 7 in the same way. Tube 8 is the standard / sample dilution solution.
[0054] Table 3 Schematic diagram of standard dilution
[0055]
[0056] 2) Sample processing: For serum or plasma samples, dilute them 2-fold using standard / sample diluent and store them at 4°C until use.
[0057] 3) Detection process:
[0058] ① Take out 50 μL from each of the diluted standard tubes 1-8 and transfer them into the corresponding wells of the 96-well plate.
[0059] ② Add 50 μL of diluted serum or plasma sample to each of the remaining sample wells.
[0060] ③ Vortex the microspheres for 30 seconds and add 50 μL of microspheres to each well.
[0061] ④ Place the 96-well plate on a shaker at 450 rpm / min for 2 min, then place in a 37°C incubator and incubate in the dark for 30 min.
[0062] ⑤ Place the 96-well plate on the magnetic plate for 5 minutes and remove the supernatant.
[0063] ⑥ Remove the 96-well plate from the magnetic plate and add 200 μL of washing solution to each well (dilute the 20× washing solution to 1× before use).
[0064] ⑦ Place the 96-well plate on the magnetic plate for 5 minutes and remove the supernatant.
[0065] ⑧ Remove the 96-well plate from the magnetic plate and add 100 μL of detection antibody to each well (before use, mix detection antibody 1 and detection antibody 2 in a volume ratio of 1:1).
[0066] ⑨ Place the 96-well plate on a shaker at 450 rpm / min for 2 min, then place in a 37°C incubator and incubate in the dark for 30 min.
[0067] ⑩Repeat steps ⑤-⑦.
[0068] Add 200 μL of washing solution to each well to resuspend the sample and detect it on flow cytometer.
[0069] Each standard and sample was tested on the machine in turn. For each microsphere group, at least 100 microspheres should be obtained. The standard gradient was used as a calibration curve to calculate the sample test results. Syndecan-4 protein and KL-6 protein both used 500U / mL as the diagnostic cut-off value. If it was greater than the cut-off value, it was judged as positive, and the rest were negative.
[0070] Example 4: Detection of clinical samples by the kit
[0071] The kit prepared by Example 3 was used to detect 100 samples collected from a hospital in Guangdong (samples were known to be RA-ILD patients and normal samples, including 50 RA-ILD patient serum samples and 50 normal serum samples). The results showed that the compliance rate of the two indicators of the kit of this study was higher than that of a single indicator (when judging by the two indicators, according to the Syndecan-4 protein test result + KL-6 protein test result greater than 1000U / ml, it was judged to be positive, and the rest were negative). The results are shown in Table 3.
[0072] Table 4 Comparison of test results of kits
[0073]
[0074] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A kit for detecting RA-ILD, characterized in that: The kit can simultaneously detect the content of Syndecan-4 protein and KL-6 protein, and the kit comprises an effective amount of KL-6 recombinant protein, an effective amount of Syndecan-4 protein, an effective amount of monoclonal antibody that simultaneously recognizes anti-Syndecan-4 protein and KL-6 protein, an effective amount of monoclonal antibody against Syndecan-4 protein, an effective amount of monoclonal antibody against KL-6 protein and matching detection reagents; the amino acid sequence of the KL-6 recombinant protein is shown in SEQ ID NO.1, wherein the codon-optimized nucleotide sequence of the KL-6 recombinant protein is shown in SEQ ID NO.2; the monoclonal antibody that simultaneously recognizes anti-Syndecan-4 protein and KL-6 protein is monoclonal antibody-2, wherein the amino acid sequences of the heavy chain variable region and the light chain variable region of monoclonal antibody-2 are shown in SEQ ID NO.4 and SEQ ID NO.
5.
2. The kit according to claim 1, characterized in that The site where the monoclonal antibody-2 binds to the Syndecan-4 protein is aa1-aa20, and its amino acid sequence is IRETEVIDPQDLLEGRYFSG.
3. The kit according to claim 1, characterized in that The site where the monoclonal antibody-2 binds to the KL-6 protein is aa231-aa250, and its amino acid sequence is ISDVSVSDVPFPFSAQSGAG.
4. The kit according to claim 1, characterized in that The monoclonal antibody-2 is coupled to magnetic particles.
5. The kit according to claim 1, characterized in that The monoclonal antibody against KL-6 protein is monoclonal antibody-6, wherein the amino acid sequences of the heavy chain variable region and the light chain variable region of monoclonal antibody-6 are shown in SEQ ID NO.6 and SEQ ID NO.
7.
6. The kit according to claim 5, characterized in that The monoclonal antibody-6 was labeled with FITC.
7. A use of the KL-6 recombinant protein as claimed in claim 1 in the preparation of a KL-6 diagnostic reagent; the amino acid sequence of the KL-6 recombinant protein is shown in SEQ ID NO.1, wherein the codon-optimized KL-6 recombinant protein nucleotide sequence is shown in SEQ ID NO.
2.
8. Use of the monoclonal antibody-2 as claimed in claim 1 in the preparation of diagnostic reagents for Syndecan-4 protein and KL-6 protein, wherein the amino acid sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody-2 are shown in SEQ ID NO.4 and SEQ ID NO.5.
